In our investigations within the 5th FP project InkCor, EVKA4-CT-2001-00049 (coordinator J. Kolar) we were interested in the inhibition of iron-gall-ink corrosion. The result of this investigation was an international patent application (in 2005); in 2010 the EU patent was assigned to this application. In our laboratory two target compounds (myo-inositol phosphates) were prepared; they were shown to prevent iron-gall-ink decay in cellulose items at the same level as phytic acid dodecasodium salt. As such they can serve as a tool for the paper documents stabilisation.
F.32 International patent
COBISS.SI-ID: 26939909The invention relates to the preparation of N-(4-(4-fluorophenyl)-6-isopropyl-5-methylpyrimidin-2-yl)-N-methylmethanesulfonamide, N-(5-(bromomethyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide and N-(4-(4-fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide, key intermediates in preparation of Rosuvastatin.
F.06 Development of a new product
COBISS.SI-ID: 34323205Members of the programme group delivered several lectures at the international conferences. The title lecture was a plenary lecture at the meeting of the Serbian Chemical Society, where SP presented synthetic aspects of nitrogen compounds. Other lecturers at the conferences in 2010: KOČEVAR, M. [plenary lecture]. 9th International Symposium of the Romanian Catalysis Society, June 23-26, 2010, Iasi, Romania. [COBISS.SI-ID 34178053] ŠTEFANE, Bogdan. [Introductory lecture]. Slovenski kemijski dnevi 2010, Maribor, 23. in 24. september 2010. [COBISS.SI-ID 34452229].
B.03 Paper at an international scientific conference
COBISS.SI-ID: 33943301Ass. Prof. Bogdan Štefane was awarded with prestigious Fulbright scholarship. In the period from October 2009 until March 2010 he was visiting scholar at the University of Maryland, USA, where he conducted research in the field of signaling pathways of bacterial virulence. His research was published in two outstanding publications (one in 2011: NAKAYAMA, S., KELSEY, I., WANG, J., ROELOFS, K., ŠTEFANE, B., LUO, Y., LEE, V. T., SINTIM, H. O. J. Am. Chem. Soc., str. 1-9; doi: dx.doi.org/10.1021/ja1091062. JCR IF (2009): 8.58, [COBISS.SI-ID 34845957].
E.02 International awards
COBISS.SI-ID: 34061573Cancer treatment requires new efficient drugs for the successful chemotherapy. Our patent application refers to analogs of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives as promising candidates to develop new drugs for the treatment of cancer patients. Refered compounds are cytotoxic in very low concentrations (IC50 0.22 to 12.8 µM), and are well soluble. Our investigations indicate that the above-mentioned compounds could be used in the treatment of cancer patients alone or in combination with other anti-cancer drugs.
F.06 Development of a new product
COBISS.SI-ID: 30639621